FXN and Friedreich ataxia: We have not achieved successful translation from in vitro to in vivo, but it remains possible that the discovery of more potent compounds in combination with a better understanding of FXN expression in FA animal models and reconsidering more complex disease mechanisms beneath R-loop formation may lead to great success in the future.